Literature DB >> 15601631

Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.

Kathy S Albain.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15601631     DOI: 10.1093/jnci/djh347

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

1.  Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.

Authors:  H Wong; S Lau; R Leung; J Chiu; P Cheung; T T Wong; R Liang; R J Epstein; T Yau
Journal:  Med Oncol       Date:  2011-10-08       Impact factor: 3.064

2.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.

Authors:  Stewart J Anderson; Irene Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Jong-Hyeon Jeong; Charles E Geyer; D Lawrence Wickerham; Joseph P Costantino; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.